Investor Readiness • Biotech • Seed → Public Markets
DEFENCE THERAPEUTICS
Turning complex science into investable narratives.
An immuno-oncology company needed to translate complex science into a clear, credible story for investors as it approached capital markets.
The Situation
Defence Therapeutics was advancing highly technical immuno-oncology science with significant potential. At the time, their focus was entirely on the science itself—not yet on translating it for external audiences.
- No defined positioning or platform narrative
- No investor-facing materials (website, deck, explainer tools)
- No visual identity to support credibility at scale
- Communication remained within internal scientific documentation
As the company approached capital markets, the gap wasn’t innovation—it was clarity.
This is a common inflection point for health and science-led companies moving toward capital markets.
The Gap
The challenge wasn’t the science. It was translation.
Scientific depth wasn’t accessible to investors
No clear positioning as a scalable platform
No narrative to support valuation or long-term vision
No visual identity to breathe life into their unique positioning
Jetty’s Strategic Role
Jetty stepped in as a strategic partner to bridge science and market—reframing the company from a collection of innovations into a cohesive, investable platform:
- Transformed complex science into a clear, investor-ready narrative
- Introduced and structured a platform model to unify the science and support scalability
- Developed sub-brand architecture to expand both perceived and actual IP value
- Aligned scientific, executive, and investor-facing communication into one cohesive system
Built the foundational assets required for capital markets:
- Website
- Investor & IPO deck
- Core messaging framework
- Explainer content to support
- scientific understanding
- A capture form and email flow for lead / list development
Before
- Internal scientific language only
- No external narrative or positioning
- Fragmented view of innovation
After
- Clear platform positioning
- Cohesive, investor-ready narrative
- Scalable story supporting multiple applications and future growth
Capital Impact
Supported multiple funding rounds and successful IPO execution
Increased investor confidence through clarity and structured positioning
Strategic Impact
Repositioned the company from early-stage science to scalable platform
Increased perceived and structural IP value through sub-brand development
Narrative Impact
Made complex immuno-oncology science accessible to broader investor audiences
Established a durable foundation for ongoing investor communications
Outputs
- Investor narrative framework
- Pitch & IPO deck
- Platform positioning strategy
- Website development
- Email funnel for leads capture / list
- building
- Sub-brand architecture
- Messaging system (scientific → investor translation)
- Explainer content for complex science
- Ongoing IR and PR communication support
Ongoing Partnership
Jetty had continued to evolve Defence Therapeutics’ narrative in real time—adapting positioning, messaging, and communication strategies as new scientific developments emerge.
Make sure you’re ready for your next big milestone.
“Jodie has been a valuable partner to us across many years and milestones. She and her company, Jetty, helped us translate complex science into a clear technology platform strategy that strengthened how we position our innovation with investors and the market. From early strategy through capital raises and our IPO, they’ve worked closely with our leadership team – continuing to shape how we frame the value of our platform, ensuring we bring the highest value to the market and new partner opportunities.”
Sebastien Plouffe, CEO
Defence Therapeutics
Bio Tech | Pre-Seed to Capital Markets